AU2009314324B2 - AKT and p70 S6 kinase inhibitors - Google Patents

AKT and p70 S6 kinase inhibitors Download PDF

Info

Publication number
AU2009314324B2
AU2009314324B2 AU2009314324A AU2009314324A AU2009314324B2 AU 2009314324 B2 AU2009314324 B2 AU 2009314324B2 AU 2009314324 A AU2009314324 A AU 2009314324A AU 2009314324 A AU2009314324 A AU 2009314324A AU 2009314324 B2 AU2009314324 B2 AU 2009314324B2
Authority
AU
Australia
Prior art keywords
imidazol
ethyl
phenyl
fluoro
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009314324A
Other languages
English (en)
Other versions
AU2009314324A1 (en
Inventor
Robert Dean Dally
Sajan Joseph
Timothy Alan Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2009314324A1 publication Critical patent/AU2009314324A1/en
Application granted granted Critical
Publication of AU2009314324B2 publication Critical patent/AU2009314324B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2009314324A 2008-11-11 2009-11-03 AKT and p70 S6 kinase inhibitors Ceased AU2009314324B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
US61/113,273 2008-11-11
PCT/US2009/063020 WO2010056563A1 (en) 2008-11-11 2009-11-03 Akt and p70 s6 kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2009314324A1 AU2009314324A1 (en) 2010-05-20
AU2009314324B2 true AU2009314324B2 (en) 2013-06-20

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009314324A Ceased AU2009314324B2 (en) 2008-11-11 2009-11-03 AKT and p70 S6 kinase inhibitors

Country Status (36)

Country Link
US (1) US8148387B2 (cg-RX-API-DMAC7.html)
EP (1) EP2358710B1 (cg-RX-API-DMAC7.html)
JP (1) JP5432275B2 (cg-RX-API-DMAC7.html)
KR (1) KR101334460B1 (cg-RX-API-DMAC7.html)
CN (1) CN102216302B (cg-RX-API-DMAC7.html)
AR (1) AR074072A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009314324B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921916A2 (cg-RX-API-DMAC7.html)
CA (1) CA2743019C (cg-RX-API-DMAC7.html)
CO (1) CO6382114A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110240A (cg-RX-API-DMAC7.html)
CY (1) CY1113409T1 (cg-RX-API-DMAC7.html)
DK (1) DK2358710T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000129A (cg-RX-API-DMAC7.html)
EA (1) EA018947B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011048A (cg-RX-API-DMAC7.html)
ES (1) ES2391704T3 (cg-RX-API-DMAC7.html)
HN (1) HN2011001247A (cg-RX-API-DMAC7.html)
HR (1) HRP20120738T1 (cg-RX-API-DMAC7.html)
IL (1) IL211940A (cg-RX-API-DMAC7.html)
JO (1) JO2822B1 (cg-RX-API-DMAC7.html)
MA (1) MA32776B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011005000A (cg-RX-API-DMAC7.html)
MY (1) MY161461A (cg-RX-API-DMAC7.html)
NZ (1) NZ592062A (cg-RX-API-DMAC7.html)
PA (1) PA8846901A1 (cg-RX-API-DMAC7.html)
PE (1) PE20110807A1 (cg-RX-API-DMAC7.html)
PL (1) PL2358710T3 (cg-RX-API-DMAC7.html)
PT (1) PT2358710E (cg-RX-API-DMAC7.html)
RS (1) RS52520B (cg-RX-API-DMAC7.html)
SI (1) SI2358710T1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000207A1 (cg-RX-API-DMAC7.html)
TW (1) TWI422587B (cg-RX-API-DMAC7.html)
UA (1) UA100190C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010056563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102549B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767064C (fr) 2009-07-02 2017-11-07 Sanofi Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
JP5581390B2 (ja) * 2009-10-23 2014-08-27 イーライ リリー アンド カンパニー Ａｋｔ阻害剤
WO2012136776A1 (en) 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors
US8927572B2 (en) * 2011-07-09 2015-01-06 Xuanzhu Pharma Co., Ltd. Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
HUE034979T2 (en) 2011-09-12 2018-05-02 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
EP3299362B1 (en) * 2012-11-16 2020-04-22 Merck Patent GmbH Imidazol-piperidinyl derivatives as modulators of kinase activity
ES2746756T3 (es) * 2013-03-11 2020-03-06 Merck Patent Gmbh Derivados de 6-[4-(1H-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de la actividad cinasa
BR112016015285A8 (pt) * 2014-02-11 2020-06-09 Merck Patent Gmbh pirimidina imidazol aminas como moduladores da atividade de quinase, seus usos e seu processo de preparação, composição farmacêutica, e kit
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
MX374576B (es) * 2016-05-20 2025-03-06 Taiho Pharmaceutical Co Ltd Derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona novedoso.
BR112022017856A2 (pt) * 2020-03-17 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
TW202328138A (zh) 2021-09-17 2023-07-16 大陸商江蘇恒瑞醫藥股份有限公司 稠合二環類衍生物的可藥用鹽、晶型及其製備方法
JPWO2024009977A1 (cg-RX-API-DMAC7.html) * 2022-07-05 2024-01-11

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075109A1 (en) * 2006-12-21 2008-06-26 Astex Therapeutics Limited Substituted piperidines having protein kinase inhibiting activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075109A1 (en) * 2006-12-21 2008-06-26 Astex Therapeutics Limited Substituted piperidines having protein kinase inhibiting activity

Also Published As

Publication number Publication date
PL2358710T3 (pl) 2012-12-31
AU2009314324A1 (en) 2010-05-20
WO2010056563A1 (en) 2010-05-20
MY161461A (en) 2017-04-14
US8148387B2 (en) 2012-04-03
TN2011000207A1 (en) 2012-12-17
EA018947B1 (ru) 2013-11-29
ZA201102549B (en) 2012-09-26
TW201022268A (en) 2010-06-16
PT2358710E (pt) 2012-10-01
ES2391704T3 (es) 2012-11-29
HRP20120738T1 (hr) 2012-10-31
EP2358710A1 (en) 2011-08-24
KR101334460B1 (ko) 2013-12-02
BRPI0921916A2 (pt) 2015-12-29
RS52520B (sr) 2013-04-30
CY1113409T1 (el) 2016-06-22
HK1158203A1 (en) 2012-07-13
DOP2011000129A (es) 2016-02-29
CN102216302B (zh) 2013-08-21
IL211940A (en) 2014-01-30
AR074072A1 (es) 2010-12-22
CN102216302A (zh) 2011-10-12
CA2743019A1 (en) 2010-05-20
ECSP11011048A (es) 2011-06-30
MA32776B1 (fr) 2011-11-01
IL211940A0 (en) 2011-06-30
CA2743019C (en) 2013-08-13
JO2822B1 (en) 2014-09-15
CO6382114A2 (es) 2012-02-15
CR20110240A (es) 2011-06-09
UA100190C2 (en) 2012-11-26
JP5432275B2 (ja) 2014-03-05
EP2358710B1 (en) 2012-08-15
HN2011001247A (es) 2013-05-20
SI2358710T1 (sl) 2012-11-30
DK2358710T3 (da) 2012-09-03
PA8846901A1 (es) 2010-06-28
US20100120801A1 (en) 2010-05-13
TWI422587B (zh) 2014-01-11
NZ592062A (en) 2013-03-28
EA201170680A1 (ru) 2011-12-30
PE20110807A1 (es) 2011-10-31
MX2011005000A (es) 2011-05-25
KR20110074578A (ko) 2011-06-30
JP2012508274A (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
AU2009314324B2 (en) AKT and p70 S6 kinase inhibitors
CA2687265C (en) P70 s6 kinase inhibitors
AU2010310786B2 (en) AKT inhibitors
EP3354652B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3478687A1 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
WO2019191470A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
KR20170005876A (ko) Ｔａｎｋ-결합 키나제 억제제 화합물
HK1158203B (en) Akt and p70 s6 kinase inhibitors
AU2017201801B2 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired